Director/PDMR Shareholding

RNS Number : 5138U
AstraZeneca PLC
01 August 2022
 

1 August 2022 17:00 BST

 

Revised stock exchange announcement due to a formatting issue with the original announcement published at 1505 today, 1 August 2022. There have been no changes to the underlying information within the release.

 

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announced that on 29 July 2022 awards of AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sarin, Executive Director and Chief Financial Officer. Each ADS represents one half of an Ordinary Share of $0.25 in the Company.

 

In accordance with the Agreement and Plan of Merger between the Company and Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's in-flight share awards granted by Alexion were converted to awards over AstraZeneca ADSs under the AstraZeneca Global Restricted Stock Plan at the time of closing of the Alexion acquisition. The awards that vested on 29 July 2022 replaced in-flight Alexion awards originally granted to Dr Sarin between February 2019 and February 2021 under the Alexion 2017 Incentive Plan.

 

Following the withholding of shares to satisfy certain tax obligations arising on vesting, 67,523 ADSs vested.

 

For tax purposes, the fair market value of an ADS at vest of the awards was US$66.72, being the closing price on the last trading day preceding the vesting.

 

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018 .

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Aradhana Sarin

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification/Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

AstraZeneca PLC American Depositary Shares

 

 

CUSIP: 046353108

 

b)

 

Nature of the transaction

 

 

Acquisition of AstraZeneca PLC American Depository Shares pursuant to a vesting under the Global Restricted Stock Plan

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

67,523

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

29 July 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUAVVRUUUWRAR

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings